

PRIOR RELATED APPLICATIONS

This application claims priority to U.S. provisional patent application serial number 60/241,008 filed October 18, 2000, U.S. provisional patent application serial number 60/270,118 filed February 22, 2001, U.S. non-provisional patent application serial number 09/714,255 filed November 17, 2000, and U.S. non-provisional patent application serial number 09/946,158 filed September 4, 2001.

5 PRIOR RELATED APPLICATIONS

10 ~~508 A2~~ This application claims priority to U.S. provisional patent application serial number 60/241,008 filed October 18, 2000, U.S. provisional patent application serial number 60/270,118 filed February 22, 2001, U.S. non-provisional patent application serial number 09/714,255 filed November 17, 2000, and U.S. non-provisional patent application serial number 09/946,158 filed September 4, 2001.

FIELD OF THE INVENTION

15 The present invention relates to novel compositions comprising electroprocessed materials with substances, and methods of making and using these compositions in delivery of substances.

FIELD OF THE INVENTION

15 The present invention relates to novel compositions comprising electroprocessed materials with substances, and methods of making and using these compositions in delivery of substances.

BACKGROUND OF THE INVENTION

Numerous methods exist for delivering substances to desired locations in vivo or in vitro. One such method uses devices or objects that contain a substance and will release the substance within a desired location. One desirable application for such methods is the administration of such objects to a location within the body of an organism, followed by the subsequent release of the desired substance into the body. In these examples, the implant often contains the substance and a carrier. After implantation, the substance is released by a variety of means including, for example, diffusion from an implant or dissolution or other degradation of a capsule coat.

BACKGROUND OF THE INVENTION

Numerous methods exist for delivering substances to desired locations in vivo or in vitro. One such method uses devices or objects that contain a substance and will release the substance within a desired location. One desirable application for such methods is the administration of such objects to a location within the body of an organism, followed by the subsequent release of the desired substance into the body. In these examples, the implant often contains the substance and a carrier. After implantation, the substance is released by a variety of means including, for example, diffusion from an implant or dissolution or other degradation of a capsule coat.

Biocompatibility is a desirable attribute in compositions designed for substance delivery. With surgical and subdermal implants, for example, the substance to be delivered is often contained in a matrix comprised of synthetic polymers. Where natural products are used in making bandages, the products typically comprise wood products such as cellulose or other materials that are not readily absorbed by the body of the recipient. Accordingly, such bandages must eventually be removed. Implants compressed from natural materials that may be

absorbed by the body are one way to improve biocompatibility and is one area in which improvements are desired.

There is also a continuing need for greater versatility and flexibility in substance delivery technology. Additional techniques for controlling release kinetics and spatial patterns of release or delivery are examples of developments that can improve substance delivery. Implants in which there is refined control of structure at the microscopic or molecular level and overall implant shape are also desired. Such methods could allow, for example, further refinements in control of pore size or other attributes that affect diffusion in and out of a matrix, or more refined control of the distribution of a substance within a matrix. New methods that allow encapsulation of living cells within a matrix are especially desired. Such methods would allow implants to contain, for example, cells that produced desired substances, cells that promote tissue growth, or cells that serve both of these functions.

What is needed therefore are new compositions for use in drug delivery that provide additional and improved methods of controlling configuration of drug delivery systems. Compositions with improved biocompatibility compared to those currently used in substance delivery and/or that can contain living cells are also needed. What is further needed are new methods of substance delivery using such compositions. Finally, methods for making such compositions are also needed.

SUMMARY OF THE INVENTION

The present invention seeks to overcome the limitations in the prior art by providing compositions comprising an electroprocessed material and a substance. The substance may be the material itself, or another substance which may be delivered with the electroprocessed material to a desired site. Sometimes the compositions comprising an electroprocessed material and a substance are in the form of a matrix. The electroprocessed materials include any natural or non-natural materials or blends thereof. The substance is released from the composition or causes the release of molecules or compounds from the composition. Substance release can occur in vitro, in vivo, or both.

The present invention also includes a method for delivery of substances to a location using the present compositions comprising an electroprocessed material and a substance. The locations can be in vitro, in vivo, or both. The

invention also includes methods for making the compositions of the present invention.

5 The compositions of the present invention include an electroprocessed material and a substance. The material can include naturally occurring materials, synthetically manufactured materials, or combinations thereof. Naturally occurring materials include natural organic or inorganic materials, genetically engineered materials and include synthetic alterations thereof. Synthetic materials include materials prepared through any method of artificial synthesis, processing, or manufacture. The invention includes materials that degrade and can absorbed by the body, or will persist in whole or in part and become portions of an extracellular tissue matrix. The compositions may be made using any electroprocessing technique, including but not limited to electrospinning, electroaerosol, electrospraying or electrosputtering techniques, or any combination thereof. Accordingly, electroprocessed droplets, particles, fibers, fibrils, or combinations thereof are all included in the compositions of the present invention. In a preferred embodiment, the electroprocessed materials form a matrix, and in some cases are similar to an extracellular matrix. Matrices may also be formed from materials that can combine to form another material, such as precursor materials. For example, fibrinogen, when combined with thrombin, will form fibrin.

20 Any material that may be electroprocessed may be used to form an electroprocessed material to be combined, either before, during or after electroprocessing, with a substance, to form the compositions of the present invention. The compositions of the present invention contain one or more substances. The substance includes any type of substance desired, with examples including molecules, cells, objects, or combinations thereof. In some cases, the substance is the electroprocessed material itself. Molecules can be any size, complexity, or type, including both organic or inorganic molecules as well as any combination of molecules. Molecules include naturally occurring and synthetic molecules. Examples of molecules include, but are not limited to therapeutics, cosmetics, nutraceuticals, vitamins, minerals, humectants, molecules produced by cells, including normal cells, abnormal cells, genetically engineered cells and cells modified through any other process. Both eukaryotic and prokaryotic cells are included in the category of substances. Substances also include, without limitation, antigens, antimicrobials, antifungals, molecules that can cause a

cellular or physiological response, metals, gases, minerals, ions, and electrically, magnetically and electromagnetically (i.e., light) reactive materials. Cells are derived from natural sources or are cultured in vitro. Combinations of different types or categories of cells can be used. Examples of objects include, but are not limited to, cell fragments, cell debris, organelles and other cellular components, tablets, viruses, vesicles, liposomes, capsules, and other structures that serve as an enclosure for molecules. It is to be understood that the composition of the present invention comprises at least one substance. Accordingly, numerous substances or combinations of similar or different substances may be combined with the electroprocessed material. The substances may be combined with the electroprocessed material through electroprocessing techniques or through other techniques. The invention also includes embodiments in which the composition comprises electroprocessed matrix materials without an additional substance. In that embodiment, the electroprocessed matrix materials may act as a substance. The present invention provides numerous uses for the compositions of the present invention, including, but not limited to, the delivery of substances to cells.

comprises electroporated cells, the electroporated cells may be used to produce the composition of the present invention. The invention provides numerous uses for the compositions of the present invention. One preferred use is the delivery of substances. Substance delivery from the compositions of the present invention can occur in vivo, for example upon or within the body of a human or animal. Substance delivery can also occur in vitro, for example within a cell culture apparatus or well. Substances delivered include those substances contained within the compositions, other substances produced by the substance contained in the composition, or both. For example, a substance may be a cell contained within the electroporated material, and the cell may synthesize and release one or more molecules. Cells may release molecules in response to signals, so that the molecules are released in a specific desired circumstance. For example, an inducible promoter in an engineered cell within an electroporated material may be used to stimulate the expression and or release of a growth factor.

30 The compositions of the present invention are versatile with respect to control of substance release from the compositions. Release kinetics of substances can be controlled by manipulating a wide variety of matrix parameters. In various embodiments, the release rate, onset of release, release of more than one compound either at the same or different times, creation of gradients of release and spatial patterns of release may be manipulated. Compositions that contain electrical or magnetic materials can be influenced to
35 move, cause motion, or produce a biological activity by applying an electric

current or a magnetic field to the composition located on or within a body, or in vitro. Electroprocessed compositions that contain light sensitive components may be designed. These compositions may move or be induced to release or bind substances in response to specific wavelengths of light. Compositions containing nucleic acids or genetically engineered cells, for example, can be used in gene therapy. Other examples include embodiments used in wound care, tissue or organ replacements, and prostheses. In some embodiments, the electroprocessed material itself contains desired properties of substances, and acts as a substance without addition of another substance. The invention thus includes a wide variety of methods of using the compositions of the present invention in medical, veterinary, agricultural, research and other applications. The compositions of the present invention provide safer and more predictable release of substances and provide a major advance in the field of substance delivery, especially drug delivery.

delivery.

The invention also includes methods for making the compositions of the present invention using any type of electroprocessing technique, combination of electroprocessing techniques, or a combination of an electroprocessing technique and another technique, such as aerosol techniques. The method includes streaming, spraying, dropping or projecting one or more solutions, fibers, or suspensions comprising the materials to be electroprocessed toward a target under conditions effective to deposit the materials on a substrate. The substances to be combined with the electroprocessed materials may be electroprocessed toward the target either before, during or after electroprocessing the material. In this manner, the substance may be incorporated within the electroprocessed material during formation, or may coat the electroprocessed material. Accordingly, one or a plurality of sources of materials and substances is used to provide the ingredients for the electroprocessed composition of the present invention. For example, collagen and a polymer such as poly glycolic acid may be electroprocessed through any combination of electrospinning and electrospraying from two sources. At the same time or at selected times thereafter, substances may be provided from other sources: for example, a third source provides a growth factor, a fourth source provides an anti-angiogenic factor, and a fifth source provides genetically altered fibroblasts. These sources of substances may provide the substances through one or more electroprocessing techniques, such as electrospin, electrospray, electroaerosol, electrosputter or any

combination thereof. These sources may also provide the substances to the electroprocessed material through non-electroprocessing techniques, such as aerosol delivery, dripping, coating, soaking or other techniques.

In one preferred embodiment, the compositions of the present invention
5 comprise one or more electroprocessed materials that form a matrix combined with at least one substance. Either the source or target is charged, and the other is grounded. The substrate upon which electrodeposition occurs can be the target itself or another object of any shape or type. For example, the substrate can be an object disposed between the orifice and the target. In one embodiment, the
10 substrate is a location on or within an organism, such as a tissue, a wound site, a desired location for substance delivery, or a surgical field in which the composition is to be applied. By manipulating process parameters, compositions of the present invention can be manufactured with a predetermined shape, for example, for depositing the material onto or into a molded substrate. Substrate
15 shape can be manipulated to achieve a specific three-dimensional structure. Targets can also be rotated or otherwise moved or manipulated during electroprocessing to control distribution of the electroprocessed material and, in embodiments involving electroprocessed fibers, the orientation of the fibers. Substances included in the composition can be combined with the matrix material
20 by any means before, during, and/or after electrodeposition.

The electroprocessed compositions may be formed into any desired shape. For purposes of substance delivery, the desired shape is dictated by the application. Non-limiting examples include the following: in the form of a patch for application to the skin; in the form of a wafer or tablet for ingestion; in the
25 form of a wafer for application to a site of removal of a glioma; in the form of a wrap to surround a tumor; in a particulate form for spraying on a surgical site; and in a particulate form for delivery of substances through inhalation.

Accordingly, it is an object of the present invention to overcome the foregoing limitations and drawbacks by providing compositions comprising an
30 electroprocessed material and a substance.

Another object of the present invention is to provide compositions comprising an electroprocessed natural material and a substance.

Yet another object of the present invention is to provide compositions comprising an electroprocessed synthetic material and a substance.

Another object of the present invention is to provide methods of protein or peptide therapy.

Still another object of the present invention is to provide methods of administering tissue and organ replacements and prostheses.

5 Another object of the present invention is to provide methods for making the compositions of the present inventions.

These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended drawings.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic drawing of an embodiment of an electroprocessing device including the electroprocessing equipment and a rotating wall bioreactor.

15 Figure 2 is a schematic drawing of an embodiment of an electroprocessing device including the electroprocessing equipment and a rotating wall bioreactor.

Figure 3 is a graph showing the release profile of vascular endothelial growth factor (VEGF) from one embodiment of the present invention obtained by electrospinning a solution comprising collagen, polylactic acid (PLA),
20 polyglycolic acid (PGA), and VEGF.

Figure 4 is a graph showing the release profile of VEGF from an embodiment of the present invention obtained by electrospinning a solution comprising collagen,
25 polylactic acid, and polyglycolic acid, and VEGF and subsequently cross-linking the electroprocessed material by exposure to glutaraldehyde vapor.

Figure 5 is a graph showing the release profile of tetracycline from several embodiments of the present invention obtained by electrospinning solutions containing tetracycline along with PLA, poly(ethylene-co-vinyl acetate) or a
30 combination of PLA and poly(ethylene-co-vinyl acetate).

Figure 6 is a graph comparing the release profile of tetracycline from an embodiment of the present invention and several other compositions. The
35 embodiment of the present invention was obtained by electrospinning a solution

containing tetracycline with poly(ethylene-co-vinyl acetate). The other compositions were periodontal fibers containing 25wt% tetracycline hydrochloride and films containing tetracycline with polylactic acid, poly(ethylene-co-vinyl acetate) or a combination of polylactic acid and poly(ethylene-co-vinyl acetate).

Figure 7 is a graph showing the release profile of tetracycline from several embodiments of the present invention obtained by electrospinning solutions containing tetracycline with poly(ethylene-co-vinyl acetate).

Figure 8 is a schematic drawing of another embodiment of an electroprocessing device including the electroprocessing equipment and a rotating wall bioreactor.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The term "substance" shall be used throughout this application in its broadest definition. The term substance includes one or more molecules, objects, or cells of any type or size, or combinations thereof. Substances can be in any form including, but not limited to solid, semisolid, wet or dry mixture, gas, solution, suspension, combinations thereof. Substances include molecules of any size and in any combination. Cells include all cell types of prokaryotic and eukaryotic cells, whether in natural state or altered by genetic engineering or any other process. Cells can be from a natural source or cultured in vitro and can be living or dead. Combinations of different types of cells can be used. Objects can be of any size, shape, and composition that may be combined with or coupled to an electroprocessed material. Examples of objects include, but are not limited to, cell fragments, cell debris, fragments of cell walls, fragments of viral walls, organelles and other cell components, tablets, viruses, vesicles, liposomes, capsules, nanoparticulates, and other structures that serve as an enclosure for molecules. The compositions of the present invention may comprise one substance or any combination of substances.

The terms "electroprocessing" and "electrodeposition" shall be defined broadly to include all methods of electrospinning, electrospraying, electroaerosoling, and electrosputtering of materials, combinations of two or more such methods, and any other method wherein materials are streamed, sprayed, sputtered or dripped across an electric field and toward a target. The

electroprocessed material can be electroprocessed from one or more grounded reservoirs in the direction of a charged substrate or from charged reservoirs toward a grounded target. "Electrospinning" means a process in which fibers are formed from a solution or melt by streaming an electrically charged solution or melt through an orifice. "Electroaerosoling" means a process in which droplets are formed from a solution or melt by streaming an electrically charged polymer solution or melt through an orifice. The term electroprocessing is not limited to the specific examples set forth herein, and it includes any means of using an electrical field for depositing a material on a target.

The term "material" refers to any compound, molecule, substance, or group or combination thereof that forms any type of structure or group of structures during or after electroprocessing. Materials include natural materials, synthetic materials, or combinations thereof. Naturally occurring organic materials include any substances naturally found in the body of plants or other organisms, regardless of whether those materials have or can be produced or altered synthetically. Synthetic materials include any materials prepared through any method of artificial synthesis, processing, or manufacture. Preferably the materials are biologically compatible materials.

One class of synthetic materials, preferably biologically compatible synthetic materials, comprises polymers. Such polymers include but are not limited to the following: poly(urethanes), poly(siloxanes) or silicones, poly(ethylene), poly(vinyl pyrrolidone), poly(2-hydroxy ethyl methacrylate), poly(N-vinyl pyrrolidone), poly(methyl methacrylate), poly(vinyl alcohol), poly(acrylic acid), polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene glycol), poly(methacrylic acid), polylactides (PLA), polyglycolides (PGA), poly(lactide-co-glycolides) (PLGA), polyanhydrides, and polyorthoesters or any other similar synthetic polymers that may be developed that are biologically compatible. The term "biologically compatible, synthetic polymers" shall also include copolymers and blends, and any other combinations of the forgoing either together or with other polymers generally. The use of these polymers will depend on given applications and specifications required. A more detailed discussion of these polymers and types of polymers is set forth in Brannon-Peppas, Lisa, "Polymers in Controlled Drug Delivery," Medical Plastics and Biomaterials, November 1997, which is incorporated by reference as if set forth fully herein.

“Materials” also include electroprocessed materials that are capable of changing into different materials during or after electroprocessing. For example, the protein fibrinogen, when combined with thrombin, forms fibrin. Fibrinogen or thrombin that are electroprocessed as well as the fibrin that later forms are included within the definition of materials. Similarly, procollagen will form collagen when combined with procollagen peptidase. Procollagen, procollagen peptidase, and collagen are all within the definition.

In a preferred embodiment, the electroprocessed materials form a matrix. The term “matrix” refers to any structure comprised of electroprocessed materials. Matrices are comprised of fibers, or droplets of materials, or blends of fibers and droplets of any size or shape. Matrices are single structures or groups of structures and can be formed through one or more electroprocessing methods using one or more materials. Matrices are engineered to possess specific porosities. Substances may be deposited within, or anchored to or placed on matrices. Cells are substances which may be deposited within or on matrices.

One preferred class of materials for electroprocessing to make the compositions of the present invention comprises proteins. Extracellular matrix proteins are a preferred class of proteins in the present invention. Examples include but are not limited to collagen, fibrin, elastin, laminin, and fibronectin. Additional preferred materials are other components of the extracellular matrix, for example proteoglycans. In each case, those names are used throughout the present application in their broadest definition. There are multiple types of each of these proteins that are naturally-occurring as well as types that can be or are synthetically manufactured or produced by genetic engineering. For example, collagen occurs in many forms and types. All of these types and subsets are encompassed in the use of the proteins named herein. The term protein further includes, but is not limited to, fragments, analogs, conservative amino acid substitutions, and substitutions with non-naturally occurring amino acids with respect to each named protein. The term “residue” is used herein to refer to an amino acid (D or L) or an amino acid mimetic that is incorporated into a protein by an amide bond. As such, the amino acid may be a naturally occurring amino acid or, unless otherwise limited, may encompass known analogs of natural amino acids that function in a manner similar to the naturally occurring amino acids (*i.e.*, amino acid mimetics). Moreover, an amide bond mimetic includes peptide backbone modifications well known to those skilled in the art.

appreciate that the protein fragments or peptides may be separated by a spacer molecule such as, for example, a peptide, consisting of one or more amino acids. Generally, the spacer will have no specific biological activity other than to join the desired protein fragments or peptides together, or to preserve some minimum distance or other spatial relationship between them. However, the constituent amino acids of the spacer may be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity. Nucleotide sequences encoding for the production of residues which may be useful in purification of the expressed recombinant protein may be built into the vector. Such sequences are known in the art. For example, a nucleotide sequence encoding for a poly histidine sequence may be added to a vector to facilitate purification of the expressed recombinant protein on a nickel column.

Once expressed, recombinant peptides, polypeptides and proteins can be purified according to standard procedures known to one of ordinary skill in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like. Substantially pure compositions of about 50 to 99% homogeneity are preferred, and 80 to 95% or greater homogeneity are most preferred for use as therapeutic agents.

Also, molecules capable of forming some of the named proteins can be mixed with other polymers during electroprocessing to obtain desired properties for uses of the formed protein in the matrix.

Throughout this application the term "solution" is used to describe the liquid in the reservoirs of the electroprocessing method. The term is defined broadly to include any liquids that contain materials to be electroprocessed. It is to be understood that any solutions capable of forming a material during electroprocessing are included within the scope of the present invention. In this application, the term "solution" also refers to suspensions or emulsions containing the material or anything to be electrodeposited. "Solutions" can be in organic or biologically compatible forms. This broad definition is appropriate in view of the large number of solvents or other liquids and carrier molecules, such as polyethylene glycol (PEG), that can be used in the many variations of electroprocessing. In this application, the term "solution" also refers to melts, hydrated gels and suspensions containing the materials, substances or anything to be electrodeposited.

35

Solvents

Any solvent that will allow delivery of the material or substance to the orifice or tip of a syringe under such conditions that the material or substance will be processed as desired may be used for dissolving or suspending the material or the substance to be electroprocessed. Solvents useful for dissolving or suspending a material or a substance will depend on the material or substance. Electrospinning techniques often require more specific solvent conditions. For example, non cross-linked fibrin monomer can be electrodeposited or electrospun from solvents such as urea, monochloroacetic acid, water, 2,2,2-trifluoroethanol, or 1,1,1,3,3,3-hexafluoro-2-propanol (also known as hexafluoroisopropanol or HFIP). Collagen can be electrodeposited as a solution or suspension in water, 2,2,2-trifluoroethanol, or HFIP. Elastin can be electrodeposited as a solution or suspension in water, 2,2,2-trifluoroethanol, isopropanol, or HFIP. Other lower order alcohols, especially halogenated alcohols, may be used. Proteins and peptides associated with membranes are often hydrophobic and thus cannot dissolve in aqueous solutions. Such proteins can be dissolved in organic solvents such as methanol, chloroform, and trifluoroethanol (TFE). Any other solvents known to one of skill in the protein chemical art may be used, for example solvents useful in chromatography, especially high performance liquid chromatography. Proteins and peptides are also soluble, for example, in HFIP, hexafluoroacetone, chloroalcohols in conjugation with aqueous solutions of mineral acids, dimethylacetamide containing 5% lithium chloride, in very dilute acids such as acetic acid and formic acid. N-methyl morpholine-N-oxide is another solvent that can be used with many polypeptides.

In functional terms, solvents used for electroprocessing have the principal role of creating a mixture with a polymer, or polymers, such that electroprocessing is feasible. The concentration of a given solvent is often an important consideration in determining the type of electroprocessing that will occur. For example, in electrospraying, the solvent should assist in the dispersion of droplets of electroprocessed material so that the initial jet of liquid disintegrates into droplets. Accordingly, solvents used in electrospraying should not create forces that will stabilize an unconfined liquid column. In electrospinning, interactions between molecules of electroprocessed material stabilize the jet, leading to fiber formation. Accordingly, for electrospun embodiments, the solvent should sufficiently dissolve or disperse the polymer to

prevent the jet from disintegrating into droplets and should thereby allow formation of a stable jet in the form of a fiber. In some embodiments, the transition from electrospraying to electrospinning can be determined by examining Brookfield viscosity measurements for polymer solutions as a function of concentration. Brookfield viscosity increases as concentration of a polymer or other material to be electroprocessed increases. Above a critical concentration associated with extensive chain entanglements of materials, however, the Brookfield viscosity will increase more rapidly with concentration, as opposed to a more gradual, linear rise with concentration at lower concentrations. For example, the Brookfield viscosity of a poly(lactide) sample obtained from Alkermes dissolved in chloroform shows an upturn in the Brookfield viscosity/concentration plot at approximately 7-8 % w/v. A sample of poly(ethylene-co-vinyl acetate) from Dupont (ELVAX 40W) shows an upturn at 14-15 % w/v. In both cases, these departures from linearity approximately coincide with the transition from electrospraying to electrospinning.

Compositions of the present invention

The electroprocessed material

One component of the compositions of the present invention is the electroprocessed material. As defined above, the electroprocessed material of the present invention can include natural materials, synthetic materials, or combinations thereof. Examples include but are not limited to amino acids, peptides, denatured peptides such as gelatin from denatured collagen, polypeptides, proteins, carbohydrates, lipids, nucleic acids, glycoproteins, lipoproteins, glycolipids, glycosaminoglycans, and proteoglycans.

Some preferred materials are naturally occurring extracellular matrix materials and blends of naturally occurring extracellular matrix materials, including but not limited to collagen, fibrin, elastin, laminin, fibronectin, hyaluronic acid, chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate, heparin sulfate, heparin, and keratan sulfate, and proteoglycans. These materials may be isolated from humans or other animals or cells or synthetically manufactured. Some especially preferred natural matrix materials are collagen and fibrin and fibronectin. Also included are crude extracts of tissue, extracellular matrix material, extracts of non-natural tissue, or extracellular matrix materials (i.e. extracts of cancerous tissue), alone or in combination.

Extracts of biological materials, including but not limited to cells, tissues, organs, and tumors may also be electroprocessed. Collagen has been electrospun to produce a repeating, banded pattern observed with electron microscopy. This banded pattern is typical of collagen fibrils produced by natural processes (i.e. banded pattern is observed in collagen when it is produced by cells). In some embodiments, collagen is electrospun such that it has a 65 nm banding pattern.

It is to be understood that these electroprocessed materials may be combined with other materials and/or substances in forming the compositions of the present invention. For example, an electroprocessed peptide may be combined with an adjuvant to enhance immunogenicity when implanted subcutaneously. As another example, an electroprocessed collagen matrix, containing cells, may be combined with an electroprocessed biologically compatible polymer and growth factors to stimulate growth and division of the cells in the collagen matrix.

Synthetic materials include any materials prepared through any method of artificial synthesis, processing, or manufacture. The synthetic materials are preferably biologically compatible for administration *in vivo* or *in vivo*. Such polymers include but are not limited to the following: poly(urethanes), poly(siloxanes) or silicones, poly(ethylene), poly(vinyl pyrrolidone), poly(2-hydroxy ethyl methacrylate), poly(N-vinyl pyrrolidone), poly(methyl methacrylate), poly(vinyl alcohol), poly(acrylic acid), polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene glycol), poly(methacrylic acid), polylactic acid (PLA), polyglycolic acids (PGA), poly(lactide-co-glycolides) (PLGA), nylons, polyamides, polyanhydrides, poly(ethylene-co-vinyl alcohol) (EVOH), polycaprolactone, poly(vinyl acetate) (PVA), polyvinylhydroxide, poly(ethylene oxide) (PEO) and polyorthoesters or any other similar synthetic polymers that may be developed that are biologically compatible. Some preferred synthetic matrix materials include PLA, PGA, copolymers of PLA and PGA, polycaprolactone, poly(ethylene-co-vinyl acetate), (EVOH), PVA, and PEO. Matrices can be formed of electrospun fibers, electroaerosol, electrosprayed, or electrosputtered droplets, or a combination of the foregoing.

In embodiments in which natural materials are used, those materials can be derived from a natural source, synthetically manufactured, or manufactured by genetically engineered cells. For example, genetically engineered proteins can be prepared with specific desired sequences of amino acids that differ from the

natural proteins. In one illustrative embodiment, desirable sequences that form binding sites on a collagen protein for cells or peptides can be included in higher amounts than found in natural collagen.

By selecting different materials, or combinations thereof, many characteristics of the electroprocessed material can be manipulated. The properties of the matrix comprised of electroprocessed material and a substance may be adjusted. As discussed in greater detail below, electroprocessed materials themselves can provide a therapeutic effect when applied. In addition, selection of matrix materials can affect the permanency of an implanted matrix. For example, matrices made of fibrin will degrade more rapidly while matrices made of collagen are more durable and synthetic matrix materials are more durable still. Use of matrices made of natural materials such as proteins also minimize rejection or immunological response to an implanted matrix. Accordingly selection of materials for electroprocessing and use in substance delivery is influenced by the desired use. In one embodiment, a skin patch of electroprocessed fibrin or collagen combined with healing promoters and anti-rejection substances may be applied to the skin and may subsequently dissolve into the skin. In another embodiment, an implant for delivery to bone may be constructed of materials useful for promoting bone growth, osteoblasts and hydroxyapatite, and may be designed to endure for a prolonged period of time.

Synthetic components, such as biocompatible substances can be used to modulate the release of materials from an electroprocessed composition. For example, a drug, or series of drugs or other materials to be released in a controlled fashion can be electroprocessed into a series of layers. One layer is composed of PGA plus a drug, the next layer PLA plus a drug, a third layer is composed of polycaprolactone plus a drug. The layered construct can be implanted, and as the successive layers dissolve or breakdown, the drug (or drugs) is released in turn as each successive layer erodes. Unlayered structures can also be used, and release is controlled by the relative stability of each component of the construct. Another advantage of the synthetic materials is that different solvents can be used. This can be important for the delivery of some materials. For example, a drug may be soluble in some organics, and using synthetics increases the number of materials that can be electroprocessed. The breakdown of these synthetic materials can be tailored and regulated in ways that are not available to natural materials. The synthetics are usually not subject to

enzymatic breakdown, and many spontaneously undergo hydrolysis. In addition to these characteristics, substances can be released from electroprocessed materials in response to electrical, magnetic and light based signals. Polymers that are sensitive to such signals can be used, or the polymers may be derivatized in a way to provide such sensitivity. These properties provide flexibility in making and using electroprocessed materials designed to deliver various substances, in vivo and in vitro.

In some embodiments of the present invention, the electroprocessed material itself provides a therapeutic effect. For example, in some embodiments electroprocessed collagen promotes cellular infiltration and differentiation, so an electroprocessed collagen matrix alone assists with healing. The P-15 site, a 15 amino acid sequence within the collagen molecule, promotes osteoblasts to produce and to secrete hydroxyapatite, a component of bone. Another example of specific sites and sequences within collagen molecules that can be manipulated and processed in a similar fashion includes the RGD binding sites of the integrin molecule. The RGD site is a sequence of three amino acids (Arg-Gly-Asp) present in many matrix materials that serves as a binding site for cell adhesion. It is recognized and bound, for example, by integrins. In addition, electroprocessed materials can be enriched with specific desired sequences before, during, or after electroprocessing. Sequences can be added in linear or other forms. In some embodiments, the RGD sequences are arranged in a cyclic form referred to as cycloRGD.

An electroprocessed material, such as a matrix, can also be composed of specific subdomains of a matrix constituent and can be prepared with a synthetic backbone that can be derivatized. For example, the RGD peptide sequence, and/or a heparin binding domain and/or other sequences, can be chemically coupled to synthetic materials. The synthetic polymer with the attached sequence or sequences can be electroprocessed into a construct. This produces a matrix with unique properties. In these examples the RGD site provides a site for cells to bind to and interact with the matrix. The heparin-binding site provides a site for the anchorage of peptide growth factors to the synthetic backbone. Angiogenic peptides, genetic material, growth factors, cytokines, enzymes and drugs are other non-limiting examples of substances that can be attached to the backbone of an electroprocessed material to provide functionality. Peptide side chains may also be used to attach molecules to functional groups on polymeric backbones.

Molecules and other substances can be attached to a material to be electroprocessed by any technique known in the art.

Another embodiment of matrix materials that have a therapeutic effect is electroprocessed fibrin. Fibrin matrix material assists in arrest of bleeding.

5 Fibrin is a component of the provisional matrix that is laid down during the early stages of healing and may also promote the growth of vasculature in adjacent regions, and in many other ways is a natural healing promoter. Fibrinogen as an electroprocessed material can also assist in healing. When placed in contact with

10 plasma from the wound and form fibrin, thereby providing the same healing properties of a fibrin material.

Substances

As discussed above, the word "substance" in the present invention is used

15 in its broadest definition. In embodiments in which the compositions of the present invention comprise one or more substances, substances can include any type or size of molecules, cells, objects or combinations thereof. The compositions of the present invention may comprise one substance or any combination of substances.

20 In embodiments in which the substances are molecules, any molecule can be used. Molecules may, for example, be organic or inorganic and may be in a solid, semisolid, liquid, or gas phase. Molecules may be present in combinations or mixtures with other molecules, and may be in solution, suspension, or any other form. Examples of classes of molecules that may be used include human or

25 veterinary therapeutics, cosmetics, nutraceuticals, agriculturals such as herbicides, pesticides and fertilizers, vitamins, amino acids, peptides, polypeptides, proteins, carbohydrates, lipids, nucleic acids, glycoproteins, lipoproteins, glycolipids, glycosaminoglycans, proteoglycans, growth factors, hormones, neurotransmitters, pheromones, chalcones, prostaglandins,

30 immunoglobulins, monokines and other cytokines, humectants, metals, gases, minerals, ions, electrically and magnetically reactive materials, light sensitive materials, anti-oxidants, molecules that may be metabolized as a source of cellular energy, antigens, and any molecules that can cause a cellular or physiological response. Any combination of molecules can be used as well as

35 agonists or antagonists.

nizatidine, norethisterone, norfloxacin, norgestrel, nortriptyline, omeprazole, ondansetron, pancreatin, panthenol, pantothenic acid, paracetamol, phenobarbital, derivatives, metabolites, and other such compounds have similar activity. Some preferred drugs or compounds include, but are not limited to, estrogen, androgen, cortisone, and cyclosporin.

Growth factors useful in the present invention include, but are not limited to, transforming growth factor- α ("TGF- α "), transforming growth factor- β ("TGF- β "), platelet-derived growth factors ("PDGF"), fibroblast growth factors ("FGF"), including FGF acidic isoforms 1 and 2, FGF basic form 2 and FGF 4, 8, 9 and 10, nerve growth factors ("NGF") including NGF 2.5s, NGF 7.0s and beta NGF and neurotrophins, brain derived neurotrophic factor, cartilage derived factor, bone growth factors (BGF), basic fibroblast growth factor, insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor (G-CSF), insulin like growth factor (IGF) I and II, hepatocyte growth factor, glial neurotrophic growth factor (GDNF), stem cell factor (SCF), keratinocyte growth factor (KGF), transforming growth factors (TGF), including TGFs alpha, beta, beta1, beta2, beta3, skeletal growth factor, bone matrix derived growth factors, and bone derived growth factors and mixtures thereof.

Cytokines useful in the present invention include, but are not limited to, cardiotrophin, stromal cell derived factor, macrophage derived chemokine (MDC), melanoma growth stimulatory activity (MGSA), macrophage inflammatory proteins 1 alpha (MIP-1alpha), 2, 3 alpha, 3 beta, 4 and 5, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TNF- α , and TNF- β . Immunoglobulins useful in the present invention include, but are not limited to, IgG, IgA, IgM, IgD, IgE, and mixtures thereof. Some preferred growth factors include VEGF (vascular endothelial growth factor), NGFs (nerve growth factors), PDGF-AA, PDGF-BB, PDGF-AB, FGFb, FGFa, and BGF.

Other molecules useful as substances in the present invention include but are not limited to growth hormones, leptin, leukemia inhibitory factor (LIF), tumor necrosis factor alpha and beta, endostatin, thrombospondin, osteogenic protein-1, bone morphogenetic proteins 2 and 7, osteonectin, somatomedin-like peptide, osteocalcin, , interferon alpha, interferon alpha A, interferon beta, interferon gamma, interferon 1 alpha, and interleukins 2, 3, 4, 5 6, 7, 8, 9, 10, 11, 12,13, 15, 16, 17 and 18.

serve the purpose of providing scaffolding or seeding, producing certain compounds, or both.

Embodiments in which the substance comprises cells include cells that can be cultured *in vitro*, derived from a natural source, or produced by any other means. Any natural source of prokaryotic or eukaryotic cells may be used. Embodiments in which the matrix is implanted in an organism can use cells from the recipient, cells from a conspecific donor or a donor from a different species, or bacteria or microbial cells. Cells harvested from a source and cultured prior to use are also included.

Some embodiments use cells that have been genetically engineered. The engineering involves programming the cell to express one or more genes, repressing the expression of one or more genes, or both. One example of genetically engineered cells useful in the present invention is a genetically engineered cell that makes and secretes one or more desired molecules. When electroprocessed matrices comprising genetically engineered cells are implanted in an organism, the molecules produced can produce a local effect or a systemic effect, and can include the molecules identified above as possible substances. Cells can also produce antigenic materials in embodiments in which one of the purposes of the matrix is to produce an immune response. Cells may produce substances to aid in the following non-inclusive list of purposes: inhibit or stimulate inflammation; facilitate healing; resist immunorejection; provide hormone replacement; replace neurotransmitters; inhibit or destroy cancer cells; promote cell growth; inhibit or stimulate formation of blood vessels; augment tissue; and to supplement or replace the following tissue, neurons, skin, synovial fluid, tendons, cartilage, ligaments, bone, muscle, organs, dura, blood vessels, bone marrow, and extracellular matrix.

Genetic engineering can involve, for example, adding or removing genetic material to or from a cell, altering existing genetic material, or both. Embodiments in which cells are transfected or otherwise engineered to express a gene can use transiently or permanently transfected genes, or both. Gene sequences may be full or partial length, cloned or naturally occurring.

Substances in the electroprocessed compositions of the present invention also comprise objects. Examples of objects include, but are not limited to, cell fragments, cell debris, organelles and other cell components, tablets, and viruses as well as vesicles, liposomes, capsules, nanoparticles, and other structures that

serve as an enclosure for molecules. In some embodiments, the objects constitute vesicles, liposomes, capsules, or other enclosures that contain compounds that are released at a time after electroprocessing, such as at the time of implantation or upon later stimulation or interaction. In one illustrative embodiment, transfection agents such as liposomes contain desired nucleotide sequences to be incorporated into cells that are located in or on the electroprocessed material or matrix. In other embodiments, cell fragments or cell debris are incorporated into the matrix. The presence of cell fragments is known to promote healing in some tissues.

5
10
15
20
Magnetically or electrically reactive materials are also examples of substances that are optionally included within compositions of the present invention. Examples of magnetically active materials include but are not limited to carbon black or graphite, carbon nanotubes, ferrofluids (colloidal suspensions of magnetic particles), and various dispersions of electrically conducting polymers. Ferrofluids containing particles approximately 10 nm in diameter, polymer-encapsulated magnetic particles about 1-2 microns in diameter, and polymers with a glass transition temperature below room temperature are particularly useful. Examples of electrically active polymers include, but are not limited to, electrically conducting polymers such as polyanilines, polypyrroles and ionically conducting polymers such as sulfonated polyacrylamides are related materials.

25
In other embodiments, some substances in the electroprocessed material or matrix supplement or augment the function of other substances. For example, when the composition comprises cells that express a specific gene, the composition can contain oligonucleotides that are taken up by the cells and affect gene expression in the cells. Fibronectin is optionally incorporated into the matrix to increase cellular uptake of oligonucleotides by pinocytosis.

30
As discussed in detail above, the electroprocessed material itself can provide a therapeutic effect. The invention thus includes embodiments involving methods of causing a therapeutic effect through delivery of an electroprocessed material to a location without incorporating additional substances in the electroprocessed material. Embodiments in which the matrix material alone is delivered as well as those in which other substances are included in the matrix are within the scope of the present invention.

Methods of Making the Composition

Electroprocessing

The method of making the compositions includes electroprocessing the materials and optionally electroprocessing the substances. As defined above, one or more electroprocessing techniques, such as electrospin, electrospray, electroaerosol, electrosputter or any combination thereof may be employed to make the electroprocessed materials and matrices in the compositions of the present invention. In the most fundamental sense, the electroprocessing apparatus for electroprocessing material includes a electrodepositing mechanism and a target substrate. The electrodepositing mechanism includes a reservoir or reservoirs to hold the one or more solutions that are to be electroprocessed or electrodeposited. The reservoir or reservoirs have at least one orifice or nozzle to allow the streaming of the solution from the reservoirs. One or a plurality of nozzles may be configured in an electroprocessing apparatus. If there are multiple nozzles, each nozzle is attached to one or more reservoirs containing the same or different solutions. Similarly, there can be a single nozzle that is connected to multiple reservoirs containing the same or different solutions. Multiple nozzles may be connected to a single reservoir. Because different embodiments involve single or multiple nozzles and/or reservoirs, any references herein to one or nozzles or reservoirs should be considered as referring to embodiments involving single nozzles, reservoirs, and related equipment as well as embodiments involving plural nozzles, reservoirs, and related equipment. The size of the nozzles can be varied to provide for increased or decreased flow of solutions out of the nozzles. One or more pumps used in connection with the reservoirs can be used to control the flow of solution streaming from the reservoir through the nozzle or nozzles. The pump can be programmed to increase or decrease the flow at different points during electroprocessing. In this invention pumps are not necessary but provide a useful method to control the rate at which material is delivered to the electric field for processing. Material can be actively delivered to the electric field as a preformed aerosol using devices such as air brushes, thereby increasing the rate of electrodeposition and providing novel combinations of materials. Nozzles may be programmed to deliver material simultaneously or in sequence.

The electroprocessing occurs due to the presence of a charge in either the orifices or the target, while the other is grounded. In some embodiments, the

nozzle or orifice is charged and the target is shown to be grounded. Those of skill in the electroprocessing arts will recognize that the nozzle and solution can be grounded and the target can be electrically charged. The creation of the electrical field and the effect of the electrical field on the electroprocessed materials or substances that will form the electroprocessed composition.

The target substrate can also be used as a variable feature in the electroprocessing of materials used to make the electroprocessed composition. Specifically, the target can be the actual substrate for the materials used to make electroprocessed matrix, or electroprocessed matrix itself is deposited.

Alternatively, a substrate can be disposed between the target and the nozzles. For instance, a petri dish can be disposed between a nozzles and a target, and a matrix can be formed in the dish. Other variations include but are not limited to non-stick surfaces between the nozzles and target and placing tissues or surgical fields between the target and nozzles. The target can also be specifically charged or grounded along a preselected pattern so that the solution streamed from the orifice is directed into specific directions. The electric field can be controlled by a microprocessor to create an electroprocessed matrix having a desired geometry. The target and the nozzle or nozzles can be engineered to be movable with respect to each other thereby allowing additional control over the geometry of the electroprocessed matrix to be formed. The entire process can be controlled by a microprocessor that is programmed with specific parameters that will obtain a specific preselected electroprocessed matrix. It is to be understood that any electroprocessing technique may be used, alone or in combination with another electroprocessing technique, to make the compositions of the present invention.

Any material that can be electroprocessed is within the method of the present invention. Forms of electroprocessed collagen include but are not limited to preprocessed collagen in a liquid suspension or solution, gelatin, particulate suspension, or hydrated gel. An example for fibrin is a preformed gel electroprocessed by subjecting it to pressure, for example by using a syringe or airbrush apparatus with a pressure head behind it to extrude the fibrin gel into the electrical field. In general, when producing fibers using electroprocessing techniques, especially electrospinning, it is preferable to use the monomer of the polymer fiber to be formed. In some embodiments it is desirable to use monomers to produce finer filaments. In other embodiments, it is desirable to include partial fibers to add material strength to the matrix and to provide

additional sites for incorporating substances. Matrix materials such as collagen in a gelatin form may be used to improve the ability of the material to dissolve. Acid extraction method can be used in preparing such gels to maintain the structure of the monomeric subunits. Units can then be treated with enzymes to alter the structure of the monomers.

In embodiments in which two materials combine to form a third material, the solutions containing these components can be mixed together immediately before they are streamed from an orifice in the electroprocessing procedure. In this way, the third material forms literally as the microfibers or microdroplets are formed in the electrospinning process. Alternatively, such matrices can be formed by electro spraying a molecule that can form matrix materials into a moist or otherwise controlled atmosphere of other molecules necessary to allow formation of the matrix to form filaments within the electric field. For example, fibrinogen can be sprayed into a moist atmosphere of thrombin. Materials such as fibrinogen that are capable of forming other materials such as fibrin can also be electro sprayed onto a target that has thrombin. Alternatively thrombin can also be electro sprayed onto a target that has fibrinogen.

In embodiments in which two or more matrix materials are combined to form a third (for example, combining fibrinogen and thrombin to form fibrin) the matrix materials can be electroprocessed in conjunction with or separately from each other, typically under conditions that do not allow the two molecules to form the third until the desired time. This can be accomplished several ways. Using fibrinogen and thrombin as an example, the two matrix materials can be electroprocessed from a solvent that does not allow thrombin to function. Alternatively, the fibrinogen or thrombin can be packaged in a carrier material. In this application the fibrinogen is electroprocessed onto the target from one solution source (by itself or with a carrier), and the thrombin is deposited in an electroaerosol manner from a separate source. The thrombin can be encapsulated and sprayed as a fine mist of particles. Alternatively, thrombin and fibrinogen can be mixed with a carrier, such as PEG, or other synthetic or natural polymers such as collagen. The carrier acts to hold the reactants in place until they are initiated. These methods are not limited to thrombin and fibrinogen and also are used with embodiments involving other combinations of matrix materials that combine to form a third material. The entire product is preferably stored under dry conditions to prevent the reaction of the two materials. When the material is

placed in a moist environment, the materials are able to combine and the product matrix material is formed.

As stated above, it is to be understood that carriers can be used in conjunction with matrix materials. Different materials, such as extracellular matrix proteins, and or substances, can be mixed with PEG or other known carriers that form filaments. For example, fibrinogen and collagen can be mixed with PEG or other known carriers that form filaments. This produces "hairy filaments" with the hair being fibrin. The "hairs" cross-link the surrounding matrix carrier into a gel, or provide reactive sites for cells to interact with the substance within the matrix carrier, such as immunoglobulins. This approach can be used for forming a matrix or gelling molecules that do not normally gel. For example, in embodiments in which a specific type of matrix material will not form filaments, then the matrix material can be combined with fibrin and PEG and electrosprayed to form an electroprocessed fibrin-containing matrix. Once fibrin formation begins, a gel of the matrix material and fibrin together is produced.

Alternatively, the material can be sputtered with another molecule that forms a sheet. Examples of molecules that form sheets include PGA, PLA, a copolymer of PGA and PLA, collagen, and fibronectin. In some embodiments, a sheet is formed with two or more materials that can combine to form a third material. This sheet can be placed in a wet environment to allow conversion to the third material.

In addition to the multiple equipment variations and modifications that can be made to obtain desired results, similarly the electroprocessed solution can be varied to obtain different results. For instance, any solvent or liquid in which the material is dissolved, suspended, or otherwise combined without deleterious effect on the process or the safe use of the matrix can be used. Materials or the compounds that form materials can be mixed with other molecules, monomers or polymers to obtain desired results. In some embodiments, polymers are added to modify the viscosity of the solution. In still a further variation, when multiple reservoirs are used, the ingredients in those reservoirs are electrosprayed separately or joined at the nozzle so that the ingredients in the various reservoirs can react with each other simultaneously with the streaming of the solution into the electric field. Also, when multiple reservoirs are used, the different

ingredients in different reservoirs can be phased in temporally during the processing period. These ingredients may include substances.

Embodiments involving alterations to the electroprocessed materials themselves are within the scope of the present invention. Some materials can be directly altered, for example, by altering their carbohydrate profile. Also, other materials can be attached to the matrix materials before, during or after electroprocessing using known techniques such as chemical cross-linking or through specific binding interactions (e.g. PDGF binds to collagen at a specific binding site). Further, the temperature and other physical properties of the process can be modified to obtain different results. The matrix may be compressed or stretched to produce novel material properties.

Still further chemical variations are possible. Fibrin, for example, is formed in different ways. Building an electroprocessed matrix comprised of fibrin, therefore, involves different ways of bringing the molecules capable of forming fibrin, such as fibrinogen and thrombin, together through electroprocessing methods. Electroprocessed materials and matrices can also be manipulated after they are formed with the electroprocessing methods.

A matrix of electroprocessed fibers, in accordance with the present invention, can be produced as described below. In the case of electrospun fibrin, while any molecules capable of forming fibrin can be used, it is preferable to electroprocess fibrinogen or thrombin to make fibrin fibers.

Electroprocessing using multiple jets of different polymer solutions and/or the same solutions with different types and amounts of substances (e.g., growth factors) can be used to prepare libraries of biomaterials for rapid screening. Such libraries are desired by those in the pharmaceutical, advanced materials and catalyst industries using combinatorial synthesis techniques for the rapid preparation of large numbers (e.g., libraries) of compounds that can be screened. For example, the minimum amount of growth factor to be released and the optimal release rate from a fibrous polymer scaffold to promote the differentiation of a certain type of cell can be investigated using the compositions and methods of the present invention. Other variables include fiber diameter and fiber composition. Electroprocessing permits access to an array of samples on which cells can be cultured in parallel and studied to determine selected compositions which serve as promising cell growth substrates.

produce different types of electroprocessed streams despite using the same voltage supply 15 through fine wires 12.

Minimal electrical current is involved in this process, and, therefore, electroprocessing, in this case electrospinning, does not denature the materials
5 that form the electroprocessed materials, because the current causes little or no temperature increase in the solutions during the procedure. In melt electrospinning, there is some temperature increase associated with the melting of the material. In such embodiments, care is exercised to assure that the materials or substances are not exposed to temperatures that will denature or otherwise
10 damage or injure them.

An electroaerosoling process can be used to produce a dense, matte-like matrix of electroprocessed droplets of material. The electroaerosoling process is a modification of the electrospinning process in that the electroaerosol process utilizes a lower concentration of matrix materials or molecules that form
15 electroprocessed materials during the procedure. Instead of producing a splay of fibers or a single filament at the charge tip of the nozzle, small droplets are formed. These droplets then travel from the charged tip to the grounded substrate to form a sponge-like matrix composed of fused droplets. In some embodiments, the droplets are less than 10 microns in diameter. In other embodiments a
20 construct composed of fibrils with droplets, like "beads on a string" may be produced. Droplets may range in size from 100 nanometers to 10 microns depending on the polymer and solvents.

As with the electrospinning process described earlier, the electroaerosol process can be carried out using various effective conditions. The same
25 apparatus that is used in the electrospinning process, for instance as shown in Figure 1, is utilized in the electroaerosol process. The differences from electrospinning include the concentration of the materials or substances that form matrix materials placed in solution in the micropipette reservoir and/or the voltage used to create the stream of droplets.

30 One of ordinary skill in the art recognizes that changes in the concentration of materials or substances in the solutions requires modification of the specific voltages to obtain the formation and streaming of droplets from the tip of a pipette.

The electroprocessing process can be manipulated to meet the specific
35 requirements for any given application of the electroprocessed compositions

that is programmed into it. Alternatively, for instance, the ground can be mounted on a frame that moves in the x, y, and z planes with respect to a stationary micropipette tip streaming collagen.

5 The substrate onto which the materials are streamed, sprayed or sputtered
can be the grounded target itself or it can be placed between the micropipette tip
and the grounded target. The substrate can be specifically shaped, for instance in
the shape of a nerve guide, skin patch, fascial sheath, or a vascular graft for
subsequent use in vivo. The electroprocessed compositions can be shaped to fit a
10 defect or site to be filled. Examples include a site from which a tumor has been
removed, an injury site in the skin (a cut, a biopsy site, a hole or other defect) and
a missing or shattered piece of bone. The electroprocessed compositions may be
shaped into shapes useful for substance delivery, for example, a skin patch, a
lozenge for ingestion, an intraperitoneal implant, a subdermal implant, the
15 interior lining of a stent, a cardiovascular valve, a tendon, a ligament a dental
prosthesis, a muscle implant, or a nerve guide. Electroprocessing allows great
flexibility and allows for customizing the construct to virtually any shape needed.
Many matrices are sufficiently flexible to allow them to be formed to virtually
any shape. In shaping matrices, portions of the matrix may be sealed to one
another by, for example, heat sealing, chemical sealing, and application of
20 mechanical pressure or a combination thereof. An example of heat sealing is the
use of crosslinking techniques discussed herein to form crosslinking between two
portions of the matrix. Sealing may also be used to close an opening in a shaped
matrix. Suturing may also be used to attach portions of matrices to one another
or to close an opening in a matrix. It has been observed that inclusion of
25 synthetic polymers enhances the ability of matrices to be heat sealed.

Other variations of electroprocessing, particularly electrospinning and
electroaerosoling include, but are not limited to the following:

1. Using different solutions to produce two or more different fibers
or droplets simultaneously (fiber or droplet array). In this case, the single
30 component solutions can be maintained in separate reservoirs.
2. Using mixed solutions (for example, materials along with
substances such as cells, growth factors, or both) in the same reservoir(s) to
produce fibers or droplets composed of electroprocessed materials as well as one
or more substances (fiber composition "blends"). Nonbiological but biologically
35 compatible material can be mixed with a biological molecule.

3. Utilizing multiple potentials applied for the different solutions or the same solutions.

4. Providing two or more geometrically different grounded targets (i.e. small and large mesh screens).

5 5. Placing the mold or mandrel or other ungrounded target in front of the grounded target.

6. Applying agents such as Teflon onto the target to facilitate the removal of electroprocessed materials from the target (i.e. make the material more slippery so that the electroprocessed materials do not stick to the target).

10 7. Forming an electroprocessed material that includes materials applied using multiple electroprocessing methods. For example, electrospun fibers and electroaerosol droplets in the same composition can be beneficial for some applications depending on the particular structure desired. This combination of fibers and droplets can be obtained by using the same
15 micropipette and solution and varying the electrical charge; varying the distance from the grounded substrate; varying the polymer concentration in the reservoir; using multiple micropipettes, some for streaming fibers and others for streaming droplets; or any other variations to the method envisioned by those of skill in this art. The fibers and droplets can be layered or mixed together in same layers. In
20 applications involving multiple micropipettes, the micropipettes can be disposed in the same or different directions and distances with reference to the target.

8. Using multiple targets.

All these variations can be done separately or in combination to produce a wide variety of electroprocessed materials and substances.

25 The various properties of the electroprocessed materials can be adjusted in accordance with the needs and specifications of the cells to be suspended and grown within them. The porosity, for instance, can be varied in accordance with the method of making the electroprocessed materials or matrix. Electroprocessing a particular matrix, for instance, can be varied by fiber
30 (droplet) size and density. If the cells to be grown in the matrix require a great deal of nutrient flow and waste expulsion, then a loose matrix can be created. On the other hand, if the tissue to be made requires a very dense environment, then a dense matrix can be designed. Porosity can be manipulated by mixing salts or other extractable agents. Removing the salt will leave holes of defined sizes in
35 the matrix.

One embodiment for appropriate conditions for electroprocessing fibrin is presented below. For electroprocessing fibrin by combining fibrinogen and thrombin, the appropriate approximate ranges are: voltage 0-30,000 volts; pH 7.0 to 7.4; calcium 3 to 10 mM; temperature 20 to 40°C; ionic strength 0.12 to 0.20 M; thrombin 0.1 to 1.0 units per ml; and fibrinogen 5 to 25 mg/ml. For electroprocessing fibrin monomer, the pH starts at 5 and increases to 7.4 while the ionic strength starts above 0.3 M and decreases to 0.1 M. The other conditions are similar as stated within this paragraph. Electroprocessed fibrin matrices of varying properties can be engineered by shifting the pH, changing the ionic strength, altering the calcium concentration, or adding additional polymeric substrates or cationic materials. For electroprocessing collagen, the appropriate approximate ranges are: voltage 0-30,000 volts; pH 7.0 to 8.0; temperature 20 to 42°C; and collagen 0 to 5 mg/ml. Electroprocessed collagen matrices of varying properties can be engineered by shifting the pH, changing the ionic strength (e.g. addition of organic salts), or adding additional polymeric substrates or cationic materials.

Shapes of Electroprocessed Materials and Matrices

Electroprocessed materials can be electrodeposited inside a specifically shaped mold. For instance, a particular type of organ or tissue that to be replaced has a specific shape, such as a skin patch to fit a biopsy site or a large scalp area following a wide area removed after discovering a malignant melanoma. That shape is then reproduced and created inside a mold designed to mimic that shape. This mold can be filled by electrodepositing the material into it. In this way, the matrix exactly mimics the mold shape. In some embodiments, matrices that will become extracellular matrices and that have a specific shape are used in the creation of a new organ. Hollow and solid organs can be made. Mixing cells with the material during electrospraying forms cells within the matrix so that they do not have to migrate into a matrix.

Methods of Combining Substances with Electroprocessed Materials

Substances can be combined with the electroprocessed materials by a variety of means. In some embodiments, the substance comprises molecules to be released from the electroprocessed material and is therefore added to or incorporated within the matrix of electroprocessed material. Substances can be

mixed in the solvent carriers or solutions of materials for electroprocessing. In this system materials can be mixed with various substances and directly electroprocessed. The resulting composition comprising an electroprocessed matrix and substance can be topically applied to a specific site and the substances released from the material as a function of the material undergoing breakdown in the surrounding environment. Substances may also be released from the electroprocessed compositions of the present invention through diffusion.

The state of the electroprocessed material in relation to the incorporated substances is dictated and can be controlled by the chemistry of the system and varies based on the selection of matrix materials, solvent(s) used, and solubility of the matrix materials in those solvents. These parameters can be manipulated to control the release of the substances (or other elements into the surrounding environment). If substances to be incorporated into the electroprocessed material are not miscible with the material, separate solvent reservoirs for the different components can be used. Mixing in such an embodiment occurs prior to, during, and/or after deposition on the target, or a combination thereof. It is to be understood that substances may be entrapped or entangled within an electroprocessed material, bonded to a material before the material undergoes electroprocessing, or bound to specific sites within the matrix material.

In a variation of this embodiment, the substance is a particle or aggregate comprising a matrix of compounds or polymers such as alginate that, in turn, contain one or more compounds that will be released from the electroprocessed material. Drugs can be combined with alginate by, for example, combining a drug suspension or drug particulate in the alginate in the presence of calcium. Alginate is a carbohydrate that forms aggregates when exposed to calcium. the aggregates can be used to trap drugs. The aggregates dissolve over time, releasing the trapped substances, such as cells trapped in alginate. The particles, which are then incorporated within the larger electroprocessed matrix, are biologically compatible but relatively stable and will degrade gradually. In some circumstances, the electroprocessed materials resemble a string of pearls. This is a physical aspect of the electroprocessing. If the polymer concentration is low, electrospraying of beads occurs. As polymer concentration increases there are some beads and some fibers. A further increase in polymer concentration leads to predominantly or all fibers. Therefore, the appearance of the pearls on a string is a transition phase.

device to produce a more laminar flow. In addition, directing the cell aerosol into matrix materials as the matrix is forming in the space between the target or mandrel and the source(s) of molecules being electroprocessed produces the effect of cushioning the cells. While not wanting to be bound by the following statement, it is believed that the cells will be trapped in the storm of filaments or other bodies produced by electrospinning or electroprocessing and pulled onto the mandrel. This situation may be less traumatic to the cells than directly spraying the cells onto a solid surface.

In one embodiment, the cells are added either before or at the same time as the materials or compounds that form electroprocessed materials are brought together. In this way, the cells are suspended throughout the three-dimensional matrix. In embodiments in which the electroprocessed material comprises fibrin formed by combining thrombin and fibrinogen, the cells are typically included in the mixture that contains the fibrinogen (whether it is plasma or purified fibrinogen). Whenever materials comprise two or more separate materials that combine to form a different material (such as fibrinogen and thrombin) bringing the materials together immediately prior to insertion into a mold, or immediately prior to the streaming step in the electrospinning process helps result in a good distribution of cells in suspension in the resulting extracellular matrix.

Cells can be added as the filaments are produced in the space between the target and polymer source. This is accomplished by dripping the cells onto the target, dripping the cells into the matrix as it forms, aerosoling the cells into the matrix or onto the target or electro spraying the cells into the matrix as it condenses and forms near or on the grounded target. In another embodiment, cells are sprayed or dribbled into a forming electroprocessed material or matrix and thereby trapped as the electroprocessed material crosses the air gap between the source solutions and target.

An alternative method to deliver cells to an electroprocessed material involves electroaerosol delivery of the cells. Cells can be deposited by electrostatic spraying at, for example, 8kV directly onto standard polystyrene culture dishes, suggesting that electrostatic cell spraying is a viable approach. Cardiac fibroblasts in phosphate buffered saline (PBS) have been electroaerosoled up to a 20 Kv potential difference. In another example, Schwann cells (rat) were plated on a PS petri dish by conventional methods after one day. Schwann cells were also electro sprayed onto a PS petri dish with a

delivered directly to an *in situ* site. For example, an electroprocessed material can be produced directly onto a skin wound, with or without substances such as molecules or cells. Additional cells or materials can then be aerosolized onto or into the wound site. Other surgical sites can also be amenable the delivery of materials using various electrodeposition techniques or combinations thereof of these methods.

In other embodiments, substances can be applied to the electroprocessed material after formation, for example by soaking the electroprocessed material in the substance or by spraying the substance onto the electroprocessed material.

Persons skilled in the art will recognize that more than one method for combining the substances with electroprocessed materials can be used in a single embodiment or application. Combining methods can be especially useful in embodiments involving release of more than one compound or compounds intended to have complex release kinetics, although such combinations are not limited to those embodiments.

15 limited to those embodiments.

Magnetically and electrically active materials can be electroprocessed, including, for example, preparing conducting polymer fibers produced by electrospinning. In addition, conducting polymers can be prepared in-situ in the matrix by, for example, incorporation of a monomer (e.g., pyrrole) followed by
20 treatment with polymerization initiator and oxidant (e.g., FeCl_3). Finally, conducting polymers can be grown in the material after electroprocessing by using a matrix-coated conductor as the anode for electrochemical synthesis of, for example, polypyrrole or polyaniline. Compounds that can form electroprocessed materials can be added to an aqueous solution of pyrrole or aniline to create a
25 conducting polymer at the anode with the entrapped electroprocessed material-forming compounds, which can then be treated with other compounds to allow formation of the material to occur.

Patterns of electroprocessed materials and substance distribution

Many embodiments of the present invention involve means for manipulating the pattern or distribution of electroprocessed materials and/or substances within an electroprocessed material. For example, an electroprocessing target can also be specifically charged or grounded along a preselected pattern so that electroprocessed materials streamed toward the target are directed into specific directions or distributions on the target or on a substrate.

Uses for the Compositions of the Present Invention

Substance delivery

One use of the compositions of the present invention is the delivery of one or more substances to a desired location. In some embodiments, the electroprocessed materials are used simply to deliver the materials itself. In other
5 embodiments, the electroprocessed materials are used to deliver substances that are contained in the electroprocessed material or that are produced or released by substances contained in the electroprocessed material. For example, an electroprocessed material containing cells can be implanted in a body and used to
10 deliver molecules produced by the cells after implantation. The present compositions can be used to deliver substances to an *in vivo* location, an *in vitro* location, or other locations. The present compositions can be administered to these locations using any method.

In the field of substance delivery, the compositions of the present
15 invention have many attributes that allow delivery of substances using a wide variety of release profiles and release kinetics. For example, selection of the substance and the method by which the substance is combined with the electroprocessed material affects the substance release profile. To the extent that the substances are not immobilized by the electroprocessed material, release from
20 the electroprocessed material is a function of diffusion. An example of such an embodiment is one in which the substance is sprayed onto the electroprocessed material. To the extent that the substances are immobilized by the electroprocessed material, release rate is more closely related to the rate at which the electroprocessed material degrades. An example of such an embodiment is
25 one in which the substance is covalently bonded to the electroprocessed material. For a substance is trapped within an electrospun aggregate or filament, release kinetics would be determined by the rate at which the surrounding material degrades or disintegrates. Still other examples are substances that are coupled to the electroprocessed material by a light sensitive bond. Exposing such a bond to
30 light releases the substance from the electroprocessed material. Conversely, in some embodiments of this invention, materials can be exposed to light to cause binding of agents *in vivo* or *in vitro*. Combining the compound with the electroprocessed material in solution, rather than in suspension, will result in a different pattern of release and thereby provide yet another level of control for the
35 process. Further, the porosity of the electroprocessed material can be regulated,

Suspending a substance in particles that are incorporated in the electroprocessed material provides another means for controlling release profile. Selection of the composition of these smaller particle matrices provides yet another way to control the release of compounds from the electroprocessed material. The release profile can be tailored by the composition of the material used in the process.

Embodiments also exist in which the substances are contained in liposomes or other vesicles in the electroprocessed matrix. Vesicles are prepared that will release one or more compounds when placed in fluids at a specific pH range, temperature range, or ionic concentration. Methods for preparing such vesicles are known to persons of skill in the art. The electroprocessed material can be delivered to a site of interest immediately or is stored either dry or at a pH at which release will not occur, and then delivered to a location containing liquids that have a pH at which release will occur. An example of this embodiment is an electroprocessed material containing vesicles that will release a desired compound at the pH of blood or other fluids released from a wound. The matrix is placed over a wound and releases fluids upon discharge of fluids from the wound.

Incorporating constituents that are magnetically sensitive or electrically sensitive into the electroprocessed material provides another means of controlling the release profile. A magnetic or electric field can then be subsequently applied to some or all of the matrix to alter the shape, porosity and/or density of the electroprocessed material. For example, a field can stimulate movement or conformational changes in the matrix due to the movement of magnetically or electrically sensitive particles. Such movement can affect the release of compounds from the electroprocessed material. For example, altering the conformation of the material can increase or decrease the extent to which the material is favorable for compound release.

In some embodiments, magnetic or electrically sensitive constituents that have been processed or co-processed with an electroprocessed material can be implanted subdermally to allow delivery of a drug over a long interval of time. By passing a magnetic field or an electrical field across the material, drug release is induced. The electroprocessed material structure is stable and does not substantially change without electromagnetic stimulation. Such embodiments provide controlled drug delivery over a long period of time. For example, an

electroprocessed material that has magnetic or electrical properties and insulin can be fabricated and placed subdermally in an inconspicuous site. By passing a magnetic field or an electrical field across the composition, insulin release can be induced. A similar strategy may be used to release compounds from a construct
 5 that has light sensitive elements, exposing these materials to light will either cause the material itself to breakdown and or cause the release of substances that are bound to the electroprocessed material by the light sensitive moiety.

In other embodiments, the substances comprise vesicles encapsulated within the electroprocessed material along with electrical or magnetic materials.
 10 The vesicles contain a compound to be released from the vesicles. Placing an electrical or magnetic field across the electroprocessed material causes the compounds within the vesicles can be released by, for example, deforming the vesicles to the point of rupture or by changing the permeability (in some cases reversibly) of the vesicle wall. Examples of these embodiments include
 15 transfection agents, such as liposomes, that contain nucleic acids that enhance the efficiency of the process of gene delivery to the cell.

In other embodiments, the composition comprising an electroprocessed material and substance is used as a transdermal patch for localized delivery of medication, or of a component of such a patch. In some of these embodiments,
 20 electrically conductive materials are incorporated into such a composition, which is then used as a component of an iontophoresis system in which one or more substances is delivered in response to the passage of electric current. Electrically conductive materials can have a direct healing effect on bone injuries. For example placing a small electric current across a fracture site promotes healing.
 25 An electroprocessed bone mimetic that conducts or produces current can be made and placed within a fracture. The addition of the electrical current will promote healing at a rate that is faster than the addition of the electroprocessed composition alone.

In other embodiments, an electroprocessed material or a portion thereof
 30 containing electromagnetic properties is stimulated by exposure to a magnet to move and thereby to apply or to release physical pressure to a pressure-sensitive capsule or other enclosure that contains molecules to be released from the material. Depending on the embodiment, the movement will affect the release relate of the encapsulated molecules.

Response of the composition to electric and magnetic fields can be regulated by features such as the composition of the electroprocessed material, size of the filaments, and the amount of conductive material added. Electromechanical response from polyaniline is the result of doping-induced volume changes, whereas ion gradients leading osmotic pressure gradients are responsible for field-induced deformation in ionic gels such as poly(2-acrylamido-2-methyl propanesulfonic acid). In each case, ion transport kinetics dominates the response, and facile transport is observed with the small fibers. Gel swelling and shrinking kinetics have been shown to be proportional to the square of the diameter of a gel fiber. Electromechanical response times of fiber bundles of less than 0.1 s, are possible in the regime of typical muscle.

Embodiments involving delivery of molecules produced by cells provide many means by which rejection and immune response to cells can be avoided. Embodiments using cells from a recipient thus avoid the problems associated with rejection and inflammatory and immunological response to the cells. In 15 embodiments in which cells from an organism other than the recipient are used, the matrix can sequester the cells from immune surveillance by the recipient's immune system. By controlling parameters such as the pore size of the electroprocessed material or matrix, nutritive support to the cells trapped in the 20 matrix can be permitted while the cells are protected from detection and response by the recipient's immune system. As an example, pancreatic islet cells that manufacture insulin collected from a donor can be encapsulated in an electroprocessed matrix and implanted in a recipient who cannot make insulin. Such an implant can be placed, for example, subdermally, within the liver, or 25 intramuscularly. For some immune responses permanent sequestration from the host system may not be necessary. The electroprocessed material can be designed to shield the implanted material for a given length of time and then begin to breakdown. In still other embodiments, bacteria or other microbial agents engineered to manufacture the desired compound can be used. This embodiment 30 provides the advantages of using cells that are more easily manipulated than cells from the recipient or a donor. Again, the electroprocessed material can serve to shield the bacteria from immune response in this embodiment. The advantage of using a bacteria carrier is that these microbes are more easily manipulated to express a wide variety of products. Embodiments in which cells are transiently 35 transfected allow for expression to be limited to a defined period. Transient

genetic engineering allows cells to revert to their original state in embodiments in which such reversion is desired to minimize the risks of complications.

In some embodiments, cells are genetically engineered such that the expression of a specific gene may be promoted or inhibited through various means known in the art. For example, a tetracycline sensitive promoter can be engineered into a gene sequence. That sequence is not expressed until the tetracycline is present. Cell markers or bacterial markers can also be used to identify the inserted material. For example, green fluorescent proteins placed within an engineered genetic material glow green when expressed. Embodiments using this feature allow verification of the viability of the cells, bacteria, or gene sequences in a matrix. The visibility of such a marker also assists in recovering an implanted electroprocessed composition.

Although the present invention provides versatility in release kinetics, embodiments also exist in which one or more substances are not released at all from the electroprocessed material. Substances may perform a function at a desired site. For example, in some embodiments, antibodies for a specific molecule are immobilized on an electroprocessed matrix and the composition is placed at a desired site. In this embodiment, the antibodies acts to bind the molecules in the vicinity of the composition. This embodiment is useful for isolating molecules that bind to an antibody. Another example is an electroprocessed matrix containing immobilized substrates that will bind irreversibly to an undesirable enzyme and thereby inactivate the enzyme.

The compositions of the present invention may be combined with pharmaceutically or cosmetically acceptable carriers and administered as compositions *in vitro* or *in vivo*. Forms of administration include but are not limited to injections, solutions, creams, gels, implants, pumps, ointments, emulsions, suspensions, microspheres, particles, microparticles, nanoparticles, liposomes, pastes, patches, tablets, transdermal delivery devices, sprays, aerosols, or other means familiar to one of ordinary skill in the art. Such pharmaceutically or cosmetically acceptable carriers are commonly known to one of ordinary skill in the art. Pharmaceutical formulations of the present invention can be prepared by procedures known in the art using well known and readily available ingredients. For example, the compounds can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers that are

may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the compositions containing the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers. Preferred unit dosage formulations are those containing a dose or unit, or an appropriate fraction thereof, of the administered ingredient. It should be understood that in addition to the ingredients particularly mentioned above, formulations comprising the compositions of the present invention may include other agents commonly used by one of ordinary skill in the art. The volume of administration will vary depending on the route of administration. For example, intramuscular injections may range in volume from about 0.1 ml to 1.0 ml.

The compositions of the present invention may be administered to persons or animals to provide substances in any dose range that will produce desired physiological or pharmacological results. Dosage will depend upon the substance or substances administered, the therapeutic endpoint desired, the desired effective concentration at the site of action or in a body fluid, and the type of administration. Information regarding appropriate doses of substances are known to persons of ordinary skill in the art and may be found in references such as L.S. Goodman and A. Gilman, eds, The Pharmacological Basis of Therapeutics, Macmillan Publishing, New York, and Katzung, Basic & Clinical Pharmacology, Appleton & Lang, Norwalk, Connecticut, (6th Ed. 1995). One desirable dosage range is 0.01 μg to 100 mg. Another desirable dosage range is 0.1 μg to 50 mg. Another desirable dosage range is 0.1 pg to 1.0 μg . A clinician skilled in the art of the desired therapy may chose specific dosages and dose ranges, and frequency of administration, as required by the circumstances and the substances to be administered. For example, a clinician skilled in the art of hormone replacement therapy may chose specific dosages and dose ranges, and frequency of administration, for a substance such as progesterone, to be administered in combination with the estrogenic and estrogenic modulatory molecules as required by the circumstances. For example, progesterone, and other progestins known to one of skill in the art may be administered in amounts ranging from about 50 μg to 300 mg, preferably 100 μg to 200 mg, more preferably 1 mg to 100 mg. Specific dosages and combinations of dosages of estrogenic and estrogenic modulatory molecules and progestins will depend on the route and frequency of

administration, and also on the condition to be treated. For example, when the composition is formulated for oral administration, preferably in the form of a dosage unit such as a capsule, each dosage unit may preferably contain 1 μ g to 5 mg of estrogenic and estrogenic modulatory molecules and 50 μ g to 300 mg of progesterone. U.S. Patent No. 4,900,734 provides additional examples of acceptable dose combinations of estrogenic molecules and progestins.

Other uses involving electrically or magnetically active constituents

The compositions of the present invention have a number of additional uses aside from substance delivery. Embodiments exist in which the incorporation of electrically or magnetically active constituents in the electroprocessed material allows the electroprocessed material to move rhythmically in response to an oscillating electric or magnetic field. Such an electroprocessed material can be used, for example, in a left ventricular assist device by providing a pumping action or a ventricular massage to a heart patient. Oscillations can be accomplished by passive movement of a magnetic or electric field with respect to the conductive material, or vice versa. By manipulating material selection, the electroprocessed material can be designed to remain in place permanently or to dissolve over time, eliminating the need for surgery to recover the device once the heart had recovered sufficiently.

Embodiments also exist in which an implanted electroprocessed material is used to convey an electric charge or current to tissue. For example, electrically active constituents can be electrically stimulated to promote neural ingrowth, stem cell differentiation, or contraction of engineered muscle, or to promote the formation of bone in orthopedic applications in which electroprocessed material is used as a carrier to reconstruct bone. In one embodiment, for example, an electroprocessed material is applied to a bone injury site and used to apply an electric current to the material to facilitate and to promote healing. The application of a small electric current to an injured bone is known to accelerate healing or promote the healing of bone injuries.

In other embodiments involving magnetically reactive materials, a magnetic field is used to position an electroprocessed material containing substances by relatively non-invasive means, for example by directing the movement of the material within the peritoneum. In other embodiments, a composition containing electrically active compounds is used to produce electric

field-driven cell migration. This approach accelerates the healing process and minimize the risk of bacterial colonization. In one example, an orthopedic implant is coated with a very thin (< 100 microns) layer of an electrically active polymer. With a very thin electrode attached to the coating, upon post-implantation, an electric field can be applied via an external electrode such that the electric field-driven cell migration is towards the implant surface. The direction can be reversed if so desired. Field orientation depends on the geometry of the implant and external electrode.

10 *Use in gene therapy*

Compositions of the present invention are also useful for testing and applying various gene therapies. By working with the compositions *in vitro*, different types of gene therapy and manipulation can be achieved by inserting preselected DNA in suspensions of cells, materials, etc. For example, nonviral techniques such as electroporation are used to treat cultured cells prior to insertion into the matrix of the present invention. In other embodiments, cells are treated within the matrix before the composition is inserted into a recipient. *In vitro* gene transfer avoids the exposure of a recipient to viral products, reduces risk of inflammation from residual viral particles and avoids the potential for germ cell line viral incorporation. It avoids the problem of finding or engineering viral coats large enough to accept large genes such as the one for Factor VIII (anti-hemophilic factor). However, *in vivo* gene therapy is accomplished in some embodiments by, for example, incorporating DNA into the electroprocessed material as it is created through the electroprocessing techniques of the present invention, whereby some DNA will be incorporated into the *in vivo* cells in contact with the composition after application of the composition to the recipient. This is especially true of small gene sequences, such as antisense oligonucleotides.

30 *Use of an electroprocessed composition as tissue or organ replacement*

The ability to combine cells in an electroprocessed material provides the ability to use the compositions of the present invention to build tissue, organs, or organ-like tissue. Cells included in such tissues or organs can include cells that serve a function of delivering a substance, seeded cells that will provide the beginnings of replacement tissue, or both. Many types of cells can be used to

create tissue or organs. Stem cells, committed stem cells, and/or differentiated cells are used in various embodiments. Also, depending on the type of tissue or organ being made, specific types of committed stem cells are used. For instance, myoblast cells are used to build various muscle structures, neuroblasts are employed to build nerves, and osteoblasts are chosen to build bone. Examples of stem cells used in these embodiments include but are not limited to embryonic stem cells, bone marrow stem cells and umbilical cord stem cells used to make organs or organ-like tissue such as livers, kidneys, etc. Examples of tissue embodiments that use differentiated cells include fibroblasts in a matrix used for a patch, for example a hernia patch, endothelial cells for skin, osteoblasts for bone, and differentiated cells like cadaver donor pancreatic islet cells for a delivery device to place these cells in a specific site, for example the liver. In some embodiments the shape of the electroprocessed composition helps send signals to the cells to grow and reproduce in a specific type of desired way. Other substances (for example, differentiation inducers) can be added to the electroprocessed matrix to promote specific types of cell growth. Further, different mixtures of cell types are incorporated into the composition in some embodiments.

embodiments.

In certain disease states, organs are scarred to the point of being dysfunctional. A classic example is cirrhosis. In cirrhosis, normal hepatocytes are trapped in fibrous bands of scar tissue. In one embodiment of the invention, the liver is biopsied, viable liver cells are obtained then cultured in an electroprocessed matrix, and re-implanted in the patient as a bridge to or replacement for routine liver transplantations.

25 Mixing of committed cell lines in a three dimensional electroprocessed matrix can be used to produce structures that mimic complex organs. For example, by growing glucagon secreting cells, insulin secreting cells, somatostatin secreting cells, and/or pancreatic polypeptide secreting cells, or combinations thereof, in separate cultures, and then mixing them together with
30 electroprocessed materials through electroprocessing, an artificial pancreatic islet is created. These structures are then placed under the skin, retroperitoneally, intrahepatically or in other desirable locations, as implantable, long-term treatments for diabetes.

In other examples, hormone-producing cells are used, for example, to replace anterior pituitary cells to affect synthesis and secretion of growth

hormone secretion, luteinizing hormone, follicle stimulating hormone, prolactin and thyroid stimulating hormone, among others. Gonadal cells, such as Leydig cells and follicular cells are employed to supplement testosterone or estrogen levels. Specially designed combinations are useful in hormone replacement therapy in post and perimenopausal women, or in men following decline in endogenous testosterone secretion. Dopamine-producing neurons are used and implanted in a matrix to supplement defective or damaged dopamine cells in the substantia nigra. In some embodiments, stem cells from the recipient or a donor can be mixed with slightly damaged cells, for example pancreatic islet cells, or hepatocytes, and placed in an electroprocessed matrix and later harvested to control the differentiation of the stem cells into a desired cell type. This procedure is performed *in vitro* or *in vivo*. The newly formed differentiated cells are introduced into the patient.

The ability to use electroprocessed materials and matrices to bioengineer tissue or organs creates a wide variety of bioengineered tissue replacement applications. Examples of bioengineered components include, but are not limited to, skeletal muscle, cardiac muscle, nerve guides, brain constructs as a filler for damaged/removed areas of the brain that are lost during accident or disease, a filler for other missing tissues, cartilage scaffoldings, sheets for cosmetic repairs, skin (sheets with cells added to make a skin equivalent), vascular grafts and components thereof, and sheets for topical applications (skin covering but no additional cells, just a patch). In some embodiments, such matrices are combined with drug and substance delivery electroprocessed matrices of the present invention in ways that will improve the function of the implant. For example, antibiotics, anti-inflammatories, local anesthetics or combinations thereof, can be added to the matrix of a bioengineered organ to speed the healing process and reduce discomfort.

One method of preparing implants of the present invention is use of a bioreactor. There are several kinds of commercially available bioreactors, devices designed to provide a low-shear, high nutrient perfusion environment. Until recently, most of the available bioreactors maintained cells in suspension and delivered nutrients and oxygen by sparging, through the use of impellers, or other means of stirring. The RCCS bioreactor (Synthecon) is a rotating wall bioreactor. It consists of a small inner cylinder, the substrate for the electropinning process, positioned inside a larger outer cylinder. Although the

muscle construct of cells arrayed and layered in a pattern of organization similar to that present in vivo. The cylindrical tissue construct is then implanted or placed within a RCCS bioreactor. Rates of rotation to maintain this type of construct in suspension range from 4-20 rpm, depending upon the over mass of the tissue and the specific materials used to fabricate the outer cylinder.

Vascularization of the engineered tissue containing electroprocessed matrix material will occur *in situ* several days after surgery. In some embodiments, neovascularization of an engineered construct containing electroprocessed material is enhanced by mixing endothelial cells into the construct during fabrication. Another alternative for supplying engineered tissue containing electroprocessed material with a vascular supply is to temporarily transplant the tissue into the omentum. The omentum has an extensive and rich vascular supply that can be used like a living incubator for the support of engineered tissue. The engineered tissue is removed from a bioreactor, wrapped in the omentum and supported by the diffusion of nutrients and oxygen from the surrounding tissue in the omentum. Alternatively, or in addition to this approach, engineered tissue is connected directly to the endogenous vascular supply of the omentum. A blood vessel can be partially perforated or cut or left dissected free of the omentum. The engineered tissue containing electroprocessed collagen, fibrin, or other materials, depending upon the construct, is wrapped around the vessel. The engineered tissue is supported by nutrients leaking from the perforated vessel or by the simple diffusion of nutrients if the vessel is left intact. Regardless of strategy, the engineered tissue is surrounded by the omentum and its rich vascular supply.

Tissue containing electroprocessed material can be engineered with an endogenous vascular system. This vascular system can be composed of artificial vessels or blood vessels excised from a donor site on the transplant recipient. The engineered tissue containing electroprocessed matrix material is then assembled around the vessel. By enveloping such a vessel with the tissue during or after assembly of the engineered tissue, the engineered tissue has a vessel that can be attached to the vascular system of the recipient. In this example, a vessel in the omentum, or other tissue is cut, and the vessel of the engineered tissue is connected to the two free ends of the omental vessel. Blood passes from the omental vessel into the vascular system of the engineered tissue, through the tissue and drains back into the omentum vessel. By wrapping the tissue in the

entire construct is, for example, cultured in a bioreactor or conventional culture or placed directly *in vivo*. For example, neovascularization can be stimulated by angiogenic and growth-promoting factors, administered, as peptides, proteins or as gene therapy. Angiogenic agents can be incorporated into the electroprocessed matrix. Nerve growth factors can be electrospun into the matrix to promote growth or neurons into the matrix and tissue. In a degradable matrix, the gradual degradation/breakdown of the matrix will release these factors and accelerate growth of desired tissues.

Electroprocessed matrices can also be used in connection with other matrix building processes. In other words, an extruded tube can have an outside layer electrospun onto it wherein the different layers complement each other and provide an appropriate matrix to promote a specific type of cell growth. As an example, a vascular graft comprised primarily of a collagen tube can have an electrospun layer of both other materials such as collagen or fibrin and cells added to promote the acceptability of the graft in a particular recipient. A second example is an *in vitro* skin preparation formed by growing fibroblasts in one layer, covering the first layer with electroprocessed collagen, and then growing a second layer composed of epidermal cells in the fibrin matrix. This layering technique can be used to make a variety of tissues.

20

Stability and Storage of the Electroprocessed Compositions

The stability of the compositions of the present invention comprising electroprocessed materials combined with substances also allows for long term storage of the compositions between formation and use. Stability allows greater flexibility for the user in embodiments in which a drug or other substance is applied after formation of the electroprocessed material, for example by soaking and spraying. A formed electroprocessed matrix can be fabricated and stored, and then the exact substance composition to be delivered to an individual patient can be prepared and tailored to a specific need shortly before implantation or application. This feature allows users greater flexibility in both treatment options and inventory management. Many electroprocessed materials are dry once they are spun, essentially dehydrated, thereby facilitating storage in a dry or frozen state. Further, the electroprocessed compositions are substantially sterile upon completion, thereby providing an additional advantage in therapeutic and cosmetic applications.

35

Storage conditions for the compositions of the present invention will depend on the electroprocessed materials and substances therein. In embodiments involving proteins, for example, it may be necessary or desirable to store the compositions at temperatures below 0°C, under vacuum, or in a lyophilized condition. Other storage conditions can be used, for example, at room temperature, in darkness, in vacuum or under reduced pressure, under inert atmospheres, at refrigerator temperature, in aqueous or other liquid solutions, or in powdered form. Persons of ordinary skill in the art recognize appropriate storage conditions for the materials and substances contained in the compositions and will be able to select appropriate storage conditions.

The compositions of the present invention and formulations comprising those compositions may be sterilized through conventional means known to one of ordinary skill in the art. Such means include but are not limited to filtration, radiation, and heat. The compositions the present invention may also be combined with bacteriostatic agents, such as thimerosal, to inhibit bacterial growth.

Formulations comprising the compositions of the present invention may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets commonly used by one of ordinary skill in the art. Preferred unit dosage formulations are those containing a dose or unit, or an appropriate fraction thereof, of the administered ingredient. It should be understood that in addition to the ingredients particularly mentioned above, the formulations of the present invention may include other agents commonly used by one of ordinary skill in the art.

The compositions of the present invention may be packaged in a variety of ways depending upon the method used for administering the composition. Generally, an article for distribution includes a container which contains the composition or a formulation comprising the composition in an appropriate form. Suitable containers are well-known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampules, plastic bags, metal cylinders, and the like. The container may also include a tamper-proof assemblage to prevent indiscreet access to the contents of the package. In

addition, the container has deposited thereon a label which describes the contents of the container. The label may also include appropriate warnings.

The present invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort can be had to various other embodiments, modifications, and equivalents thereof, which, after reading the description herein, can suggest themselves to those skilled in the art without departing from the spirit of the present invention.

10 EXAMPLE 1

Fibroblast growth factor (FGF, obtained from Chemicon, Temecula, CA) was dissolved in a solution of matrix material comprised of type I collagen (80%), PGA (10%) and PLA (10%). The percentages refer to the weight of the materials with respect to one another. These materials were dissolved in HFIP at a final concentration of 0.08 gm per ml. Sufficient FGF was added to 1 ml of solution to provide an FGF concentration of 50 ng/ml of the collagen/PGA/PLA electrospinning solution. The material was electrospun into the shape of a cylinder onto the outer surface of a grounded and spinning 16 gauge needle about 25-35 mm in length. After application, the cylinder was sutured shut looping a suture around the outside of the construct and pulling tight to seal the ends. Alternatively, a hot forceps is used to pinch the ends together and literally heat seal the ends shut. These methods formed a hollow, enclosed construct. The construct was then surgically implanted within the vastus lateralis muscle of a rat. The construct was left in place for seven days and recovered for inspection. FGF in the matrix accelerated muscle formation within the electrospun matrix by promoting muscle formation within the wall of the electrospun cylinder.

EXAMPLE 2

Vascular endothelial growth factor (VEGF, obtained from Chemicon, Temecula, CA) was dissolved in a solution of matrix material comprised of type I collagen (80%), PGA (10%) and PLA (10%) as described in EXAMPLE 1. These materials were dissolved in HFIP at a final concentration of 0.08 gm per ml. Sufficient VEGF was added to 1 ml of solution to provide a VEGF concentration of 50 ng/ml of the collagen/PGA/PLA electrospinning solution. The material was electrospun to form a construct and implanted into a rat muscle

using the same procedures set forth in Example 1. VEGF increased the density of functional capillaries that were present throughout the construct. This was evidenced by the presence of capillaries containing red blood cells (RBCs).

EXAMPLE 3

5 Constructs of electroprocessed collagen and PGA:PLA copolymer, with VEGF spun into the matrix were prepared using 80% collagen and 20% PGA:PLA. The collagen and PGA:PLA were dissolved in HFIP at a final combined concentration of 0.08 gm per ml. Solutions were prepared in which
10 different amounts of VEGF were added to 1 ml of the solution of collagen and PGA:PLA copolymer. Separate solutions were prepared containing 0 ng, 25 ng, 50 ng, and 100 ng each in 1 ml. Constructs were prepared for each solution by electrospinning one ml. The constructs were cut into smaller sections and placed in a phosphate buffer solution (PBS). Release of VEGF into the PBS was
15 measured as a function of time by the ELISA method. The ELISA kit for VEGF was purchased from Chemicon International (part number cyt214) and the directions provided in the kit were followed to perform the ELISA. Samples were centrifuged to remove particulate matter and stored at -20 °C prior to use.

An identical construct was subjected to crosslinking by exposing it to
20 glutaraldehyde vapor at room temperature and subjected to an identical ELISA assay. A sample of the electroprocessed construct was placed in a 100 mm tissue culture dish. A 35 mm tissue culture dish containing 1 ml of 50% glutaraldehyde was placed inside the 100 mm tissue culture dish. The lid of the 100 mm tissue culture dish was replaced and the sample was allowed to sit for 15 minutes at
25 room temperature. The sample was rinsed in sterile water or culture media. The amount of VEGF (expressed in picograms per 1 mg of electrospun material) for the non cross-linked and cross-linked samples was measured at different times are presented in Figures 3 and 4, respectively.

In Figure 3 and Figure 4, the open diamonds represent release from the
30 fibers electrospun from the solution containing PGA:PLA copolymer and collagen to which no VEGF was added. The open squares represent release from fibers electrospun from the solution containing PGA:PLA copolymer and collagen to which 25 ng of VEGF were added. The open circles represent release from the fibers electrospun from a solution containing PGA:PLA copolymer and
35 collagen to which 50 ng of VEGF were added. The open triangles represent

release from the fibers electrospun from a solution containing PGA:PLA copolymer and collagen to which 100 ng of VEGF were added. Results demonstrate not only that the matrix releases VEGF in PBS but also that cross-linking with glutaraldehyde slows release from the matrix.

5

EXAMPLE 4

Polyethylene-co-vinyl acetate (PEVA) was a gift from DuPont (Elvax 40, 40 vinyl acetate). PEVA pellets were soaked in ethanol for several days to remove antioxidants. Poly(lactic acid) (100 L PLA) was a gift from by Alkermes, Inc. (Medisorb®) with a number-average molecular weight, M_n , of 205 KD and polydispersity of 1.7. All solvents were analytical grade and were used as received. Tris(hydroxymethyl)aminomethane hydrochloride (Trizma® HCl) and trishydroxymethylaminomethane (Trizma®-base) were supplied by Sigma and were used without further purification to prepare buffer solutions of pH 7.35. Tetracycline hydrochloride was also obtained from Sigma. Actisite® periodontal fiber (0.5mm PEVA) containing 25wt% tetracycline hydrochloride was a gift from Alza Corporation (Palo Alto, CA).

Electrospinning was carried out using 14 % wt/v solutions of 100% PEVA, 100% PLA, or mixtures of the two in chloroform. The mixtures used were 25% PEVA/75% PLA, 50%/50% of each, and 75% PEVA/25% PLA, with percentages by weight. Tetracycline hydrochloride, which is insoluble in chloroform, was solubilized in a small amount of methanol and added to the polymer solutions prior to electrospinning. The resulting solutions were yellow but clear, indicating homogeneous solubilization of both the polymers and drug.

The electrospinning set-up consisted of a glass pipette (held parallel to ground or angled at 45° downward), 0.32 mm diameter silver-coated copper wire (positive lead), a copper sheet (ground electrode) ca. 30 cm from the pipette, and a Spellman CZE100OR high voltage supply. A positive voltage (15 kV) was applied through the copper wire to the polymer solution inside the glass pipette. The solutions were delivered via syringe pumps to control the mass flow rate, which ranged from 10-18 ml/h. More conveniently, the solution can be held in a plastic syringe with the high voltage supply connected to the metal syringe needle. The solutions were delivered via syringe pumps to control the mass flow

rate, which ranged from 10-18 ml/h. The resulting electrically charged fibers were collected on a rotating metal plate to produce a sheet of non-woven fabric.

A 100L PLA containing 5% tetracycline hydrochloride (by weight) was electrospun from 14% W/V solution in chloroform, with a mass flow rate of the polymer solution between 18-21 ml/h. PEVA containing 5% tetracycline hydrochloride (expressed herein as by weight of total polymer) was electrospun from 14 % W/V solution with a mass flow rate of 3 ml/h. Blends containing 5% tetracycline hydrochloride and consisting of 25% PLA and 75% PEVA were electrospun at mass flow rates of 13-18 ml/h. A 50/50 PLA/PEVA blend with 5% tetracycline hydroxide was spun at a mass flow rate of 10-13 ml/h. A 50/50 PLA/PEVA blend with 25% tetracycline hydroxide (by weight of total polymer weight) was spun at a mass flow rate of 15ml/hr. A blend containing 75/25 PLA/PEVA with 5% tetracycline hydroxide was spun with a mass flow rate of 17 ml/h. The collected 'fabric' was used for studying the release of tetracycline hydrochloride.

For comparative purposes, cast films were made from different compositions of PLA and PEVA. As with the fibers, films were made of 25% PEVA/75% PLA, 50%/50% of each, and 75% PEVA/25% PLA and 5% tetracycline hydrochloride was added to each. The solutions in chloroform were cast onto glass petri dishes, left at room temperature until the chloroform was evaporated, then dried at 25 °C under vacuum for 3 hours. The release of tetracycline hydrochloride from ACTISITE® (PEVA) periodontal fiber was also compared.

Release of tetracycline hydrochloride was determined using UV-VIS measurements carried out at Perkin-Elmer UV/VIS Lambda 40 Spectrophotometer. The molar extinction coefficient for tetracycline hydrochloride in Tris buffer was found to be 15,800 from a linear Beer-Lambert plot of absorbance at 360 nm vs. concentration. Release of tetracycline hydrochloride was determined by placing a known mass of polymer and drug in tris buffer and monitoring the absorbance at 360 nm as a function of time. The buffer solution was changed if the released drug gave absorbance higher than 2.0. Data are reported as the % tetracycline hydrochloride released based upon the expected amount in the samples from the feed composition. The morphology of the electrospun samples were studied with JSM-820 Scanning electron microscope (JEOL Ltd.).

The release profiles of tetracycline hydrochloride from electrospun fibers and the cast films are shown in Figures 5 and 6. In Figure 5, the solid diamonds denote release from the fibers electrospun from the solution in which the polymer was 50% EVA and 50% PLA and 5% tetracycline was added. The open circles
5 denote release from the fibers electrospun from the solution in which the polymer was 50% EVA and 50% PLA and 25% tetracycline was added. The open triangles denote release from the fibers electrospun from the solution in which the polymer was 100% PLA and 5% tetracycline was added. The solid squares
10 denote release from the fibers electrospun from the solution in which the polymer was 100% EVA and 5% tetracycline was added.

In Figure 6, the open diamonds denote release from the fibers electrospun from the solution containing 100% EVA. The open squares denote release from the ACTISITE® (PEVA) periodontal fiber. The open triangles denote release from the film in which the polymer was 50% PLA and 50% PEVA. The open
15 circles denote release from the film in which the polymer was 25% PLA and 75% PEVA. The solid diamonds connected by a thick line denote release from the film containing 100% PLA. The solid triangles denote release from the film in which the polymer was 75% PLA and 25% PEVA. The solid squares denote
20 release from the fibers electrospun from the solution containing 25% PLA and 75% PEVA. The solid diamonds connected by a thin line denote release from film containing 100% EVA.

Electrospun EVA showed a higher release rate than the mats derived from PLA/EVA (50/50) or pure PLA. Electrospun PEVA released 65% of its drug content within 100 hours, whereas the electrospun 50/50 mixture of PEVA and
25 PLA released about 40% over the same time period. Mats of PLA fibers with no PEVA exhibit some instantaneous release, with negligible release over 50 hours. The 50:50 sample with 25wt% tetracycline hydrochloride releases the drug more rapidly than the 5% sample, although the % released of the former approaches that of the latter after 150 hrs.

30 Figure 7 shows release profiles of three electrospun PEVA samples, two from the same batch of mat and another from a different preparation under identical conditions. The release amounts of each sample are denoted by solid diamonds, solid squares, and open triangles, respectively. The profiles are quite similar indicating very good reproducibility. In general, the initial rate of release
35 of all formulations including ACTISITE® (denoted as Alza) is high during the

first 10-12 hours, most likely due to release of drug sequestered on the sample surfaces. The total percent released from the cast films (Figure 6) were lower than that of the electrospun mats, as would be expected due to the much lower surface area of the former. The PLA/EVA 75/25 film released 30% of its tetracycline hydrochloride in 120 hrs, whereas the film of 50/50 PLA/EVA showed a slightly lower percent of release (25%) in the same period of time. Release from the PLA film was much lower, only 6% released in 120 hrs, whereas the PEVA film showed 8% release over the same period.

EXAMPLE 5

A mixture of cultured insulin secreting cells is seeded into an electroprocessed collagen matrix to form an electroprocessed collagen-containing tissue. The electroprocessed matrix containing the insulin secreting cells is implanted into a diabetic recipient in need of insulin. This electroprocessed collagen or fibrin-containing tissue optionally contains a vessel. The matrix is implanted into the retroperitoneal space and the vessel is anastomosed into the hepatic portal circulation. Insulin is released from the insulin-containing cell and transmitted to the circulation.

The electroprocessed matrix containing the insulin secreting cells is optionally supplemented with cells that synthesize and secrete glucagon, somatostatin, pancreatic polypeptide, or combinations thereof, in order to mimic the hormonal complement of the pancreatic islet.

Optionally, heterologous cells, (for example, engineered bacteria or cells from a conspecific donor) are placed in a matrix with a pore size that will allow diffusion of nutrients to the cells but does not allow or inhibits or delays the detection of the cells by the recipient's immune system.

EXAMPLE 6

Keratinocytes are harvested from a healthy site of a patient suffering from a chronic wound. The cells are grown in culture and transfected by electroporation to express VEGF. Next, the transfected cells are mixed or prepared in an electrospun collagen matrix. Antisense oligonucleotide for matrix metalloproteinases (MMPs) are also spun into the matrix. The matrix is topically applied to the surface of the wound. The cells near and in the implant take up the antisense sequences, express their transfected gene sequences and MMP

production is reduced. In other applications the cells may be genetically engineered to secrete VEGF, thereby promoting healing. Release of the antisense oligonucleotides suppress expression of MMPs, which are typically overexpressed in a chronic wound. Thus the wound site is repaired with an implant that simultaneously promotes natural healing responses. Optionally, the matrix is comprised of fibrin or a mix of fibrin and collagen. The fibrin assists in cessation of bleeding and promotes healing.

EXAMPLE 7

Osteoblasts from a patient with a bone injury are cultured and incorporated into an electrospun matrix comprising type I collagen. The matrix is formed in the shape of a cavity or defect at the injury site. Bone growth factor (BGF), bone morphogenic protein (BMP) or sequences of genes encoding for these proteins, are electrospun into the matrix are optionally incorporated into the electrospun matrix. The matrix assists in growth of new bone, and the BGF or BMP in the matrix promotes bone growth.

Optionally, the collagen used is produced *in vitro* by genetically engineered cells that express a collagen polymer with more P-15 sites than in normal collagen. The excess of P-15 sites promotes osteoblasts to produce and secretes hydroxyapatite and further aid bone growth.

Optionally, the matrix is further electroprocessed with polypyrroles, which are electrically active materials. Electrodes are attached to each end of the implanted matrix. Charged electrodes are later applied to the surface over the electrodes to create a small electric current across the implant to further facilitate healing of the bone injury. In another embodiment piezoelectric elements may be electrospun into the matrix to produce electric discharges that promote healing.

EXAMPLE 8

In another example, similar to that described for skeletal muscle a cardiac patch is prepared. A sheet of electroprocessed material is prepared with aligned filaments of collagen. The sheet is folded into a pleated sheet in the desired shape and or rolled into a cylinder. A second construct is electrospun in the desired shape, for example a rectangle. The pleated sheet that mimics the cellular layers of the intact heart is inserted into the electroprocessed rectangular form. The construct is filled with cells, sutured shut and placed in a bioreactor or directly in

